top of page

Biopharma Pulse - 4/25 - 4/29 Week in Review

As we have reached the end of April, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on compared to XBI.

Table 1. BPIQ company weekly/monthly moves and YTD moves


Weekly Move

YTD Move

All BPIQ Companies



CAR-T Companies



Gene Editing Companies






See the biggest moves from last week below:


Don't miss upcoming catalysts.. Get our weekly Catalyst Watchlist Free!

*We never send you spam - unsubscribe anytime


Highlights for the week of 4/25-4/29

Biggest positive move

  • $NKTX +140.9% Announced positive data then issued an offering.

Biggest negative move

  • $ELYM -55.8% Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs - ETX-810 Ph 2a failed and delayed enrollment in ETX-155 ph 2a.

Additional big moves

  • $PTGX -39.4% Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis

  • $ARDX +31.8% Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor).

  • $AVDL -36.0% Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting.

  • $VERU +25.8% Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious Diseases.

  • $PRTA -14% Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease.

  • $AVDL +26% Avadel Pharmaceuticals Provides Comment on Recent Trading Activity.

  • $ERYP -23% Disposition of certain assets and inventory to Catalent.

  • $SLDB -17.0% Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy source

  • $FNCH +33.8% Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND source

  • $ZYME +33.1% Zymeworks Reports Last Patient Enrolled In Pivotal Study Of Zanidatamab In Treatment Of HER2-Expressing Late-Line Biliary Tract Cancer source

  • $GNCA -24.1% Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives source

Highlights for next week

  • To see next week's Big Movers HERE, subscribe. Learn more here.

  • Keep an eye out for upcoming updates on ASCO

  • PDUFA target action dates: $SUPN, $HCM, $CHRS, and $AXSM

See our Big Movers post to learn about upcoming Movers throughout April and PDUFAs, after subscribing. Learn more here.

bottom of page